KR20220130822A - 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법 - Google Patents

칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법 Download PDF

Info

Publication number
KR20220130822A
KR20220130822A KR1020227031076A KR20227031076A KR20220130822A KR 20220130822 A KR20220130822 A KR 20220130822A KR 1020227031076 A KR1020227031076 A KR 1020227031076A KR 20227031076 A KR20227031076 A KR 20227031076A KR 20220130822 A KR20220130822 A KR 20220130822A
Authority
KR
South Korea
Prior art keywords
antibody
subject
headache
cgrp
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227031076A
Other languages
English (en)
Korean (ko)
Inventor
마르셀로 비갈
사라 월터
헨리 스턴
마이클 창
Original Assignee
테바 파마슈티컬스 인터내셔널 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54141465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20220130822(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 테바 파마슈티컬스 인터내셔널 게엠베하 filed Critical 테바 파마슈티컬스 인터내셔널 게엠베하
Priority to KR1020247032452A priority Critical patent/KR20240146107A/ko
Publication of KR20220130822A publication Critical patent/KR20220130822A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
KR1020227031076A 2014-03-21 2015-03-20 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법 Ceased KR20220130822A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247032452A KR20240146107A (ko) 2014-03-21 2015-03-20 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201461968897P 2014-03-21 2014-03-21
US61/968,897 2014-03-21
US201462083809P 2014-11-24 2014-11-24
US62/083,809 2014-11-24
US201562119778P 2015-02-23 2015-02-23
US62/119,778 2015-02-23
KR1020207031034A KR20200126018A (ko) 2014-03-21 2015-03-20 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
PCT/US2015/021887 WO2015143409A1 (en) 2014-03-21 2015-03-20 Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207031034A Division KR20200126018A (ko) 2014-03-21 2015-03-20 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247032452A Division KR20240146107A (ko) 2014-03-21 2015-03-20 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법

Publications (1)

Publication Number Publication Date
KR20220130822A true KR20220130822A (ko) 2022-09-27

Family

ID=54141465

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020227031076A Ceased KR20220130822A (ko) 2014-03-21 2015-03-20 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
KR1020247032452A Ceased KR20240146107A (ko) 2014-03-21 2015-03-20 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
KR1020207031034A Ceased KR20200126018A (ko) 2014-03-21 2015-03-20 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
KR1020167029438A Active KR102274964B1 (ko) 2014-03-21 2015-03-20 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020247032452A Ceased KR20240146107A (ko) 2014-03-21 2015-03-20 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
KR1020207031034A Ceased KR20200126018A (ko) 2014-03-21 2015-03-20 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
KR1020167029438A Active KR102274964B1 (ko) 2014-03-21 2015-03-20 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법

Country Status (27)

Country Link
US (3) US9896502B2 (enExample)
EP (2) EP4324481A3 (enExample)
JP (5) JP6568099B2 (enExample)
KR (4) KR20220130822A (enExample)
CN (3) CN106456759A (enExample)
AU (1) AU2015230933B2 (enExample)
BR (1) BR112016021423A2 (enExample)
CA (1) CA2943551A1 (enExample)
CL (1) CL2016002375A1 (enExample)
DK (1) DK3119431T3 (enExample)
EA (1) EA201691787A1 (enExample)
ES (1) ES2974803T3 (enExample)
FI (1) FI3119431T3 (enExample)
HR (1) HRP20240159T1 (enExample)
HU (1) HUE065397T2 (enExample)
IL (2) IL247853B (enExample)
LT (1) LT3119431T (enExample)
MX (2) MX378344B (enExample)
PE (2) PE20220337A1 (enExample)
PL (1) PL3119431T3 (enExample)
PT (1) PT3119431T (enExample)
RS (1) RS65360B1 (enExample)
SI (1) SI3119431T1 (enExample)
SM (1) SMT202400131T1 (enExample)
UA (1) UA123759C2 (enExample)
WO (1) WO2015143409A1 (enExample)
ZA (1) ZA201606745B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
SI3045182T1 (en) 2005-11-14 2018-08-31 Teva Pharmaceuticals International Gmbh An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
KR101304150B1 (ko) 2008-03-04 2013-09-05 라브리스 바이올로직스 인코포레이티드 만성 통증의 치료 방법
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
TWI728953B (zh) 2015-04-24 2021-06-01 美商安美基公司 治療或預防偏頭痛之方法
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
TW201725212A (zh) * 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
SMT202600087T1 (it) * 2016-09-23 2026-03-09 Teva Pharmaceuticals Int Gmbh Trattamento dell’emicrania refrattaria
JP7195262B2 (ja) 2017-03-02 2022-12-23 ベス イスラエル デアコネス メディカル センター インコーポレイティッド カルシトニン遺伝子関連ペプチドを指向する抗体に応答性の頭痛患者の選択方法
SG11202009629YA (en) 2018-04-02 2020-10-29 Amgen Inc Erenumab compositions and uses thereof
US10899826B1 (en) 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
CR20210373A (es) 2019-01-08 2021-08-19 H Lundbeck As Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
WO2020163866A1 (en) * 2019-02-08 2020-08-13 Schedule 1 Therapeutics, Inc. Compositions comprising cannabinoids and methods of use thereof
GEAP202515803A (en) 2019-05-02 2025-06-10 H Lundbeck As Treatment of headache using anti-cgrp antibodies
CN114127110B (zh) * 2019-05-30 2022-07-01 山东博安生物技术股份有限公司 抗cgrp抗体及其应用
KR20210124867A (ko) * 2020-04-06 2021-10-15 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료
CA3183934A1 (en) * 2020-05-29 2021-12-02 Amgen Inc. Antibody formulations and uses thereof

Family Cites Families (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3662333A (en) 1970-09-08 1972-05-09 Bendix Corp Hydraulic accumulator charge detector and indicating system
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JPS62129297A (ja) 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
IE71195B1 (en) 1989-07-10 1997-02-12 Amylin Corp Use of an amylin antagonist for the manufacture of a medicament for the treatment of obesity and essential hypertension and related disorders
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
EP0644946A4 (en) 1992-06-10 1997-03-12 Us Health VECTOR PARTICLES RESISTANT TO INACTIVATION BY HUMAN SERUM.
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1994021665A1 (en) 1993-03-24 1994-09-29 Amylin Pharmaceuticals, Inc. Cloned receptors and methods for screening
AU6818094A (en) 1993-04-22 1994-11-08 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
GB9316989D0 (en) 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
WO1995007994A2 (en) 1993-09-15 1995-03-23 Viagene, Inc. Recombinant alphavirus vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
HUT75162A (en) 1993-11-16 1997-04-28 Depotech Corp Vesicles with controlled release of actives
JPH07196700A (ja) 1994-01-06 1995-08-01 Sando Yakuhin Kk 抗カルシトニン抗体及びその作製方法、並びに該抗体を用いたカルシトニンの測定方法
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
DE69433747D1 (de) 1994-08-16 2004-06-03 Human Genome Sciences Inc Calcitoninrezeptor
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
FR2732222B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
FR2732220B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue
EP0737471A3 (fr) 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
FR2732598B1 (fr) 1995-04-10 1997-05-09 Oreal Utilisation de sel de metaux alcalino-terreux pour le traitement des prurits et des dysesthesies oculaires ou palpebraux
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
EP0851759A4 (en) 1995-09-05 2000-12-06 Smithkline Beecham Corp COMPOUNDS AND RELATED METHODS
WO1997041223A1 (en) 1996-04-15 1997-11-06 The University Of Miami Molecular clone of cgrp receptor component protein and uses thereof
DE69739286D1 (de) 1996-05-06 2009-04-16 Oxford Biomedica Ltd Rekombinationsunfähige retrovirale vektoren
US5746694A (en) 1996-05-16 1998-05-05 Wilk; Peter J. Endoscope biopsy channel liner and associated method
WO1998003534A1 (en) 1996-07-23 1998-01-29 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
EP0934068A1 (en) 1996-09-09 1999-08-11 Smithkline Beecham Corporation Compounds and methods
DE59711622D1 (de) 1996-09-10 2004-06-17 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1998056779A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
US20030069231A1 (en) 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
WO1999018792A1 (en) 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
SE9704770D0 (sv) 1997-12-19 1997-12-19 Astra Ab New use
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
JP2002525371A (ja) 1998-09-30 2002-08-13 メルク シャープ エンド ドーム リミテッド Ｃｇｒｐリガンドとしてのベンゾイミダゾリニルピペリジン
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1031350A1 (en) 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
WO2000053211A2 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
US6521609B1 (en) 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US20020162125A1 (en) 2001-03-06 2002-10-31 Anne-Marie Salmon Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal
DE60234944D1 (de) 2001-09-27 2010-02-11 Merck & Co Inc Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodiered assayverfahren
US6767056B2 (en) 2002-01-14 2004-07-27 Shin Yeh Enterprise Co., Ltd. Settee with a foldable tray-support unit
ES2327830T3 (es) 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
US7879991B2 (en) 2002-05-06 2011-02-01 Noxxon Pharma Ag CGRP binding nucleic acids
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US7097467B2 (en) 2002-06-03 2006-08-29 Wan-Tien Chen Dustproof plate fixture for an electrical connector
ES2616539T3 (es) 2002-06-05 2017-06-13 Bristol-Myers Squibb Company Antagonistas de receptores de péptidos relacionados con el gen de calcitonina
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
MXPA05001649A (es) 2002-08-12 2005-05-27 Birkir Sveinsson Uso de compuestos antagonistas del cgrp para tratamiento de la psoriasis.
WO2004032870A2 (en) * 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
JP4754219B2 (ja) 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
DK1575517T3 (da) 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
EP1606286B1 (en) 2003-03-14 2011-05-11 Merck Sharp & Dohme Corp. Benodiazepine spirohydantoin cgrp receptor antagonists
AU2004222328B2 (en) 2003-03-14 2009-10-08 Merck Sharp & Dohme Corp. Aryl spirohydantoin CGRP receptor antagonists
US7288559B2 (en) 2003-03-14 2007-10-30 Merck + Co, Inc. Carboxamide spirohydantoin CGRP receptor antagonists
EP1606264B1 (en) 2003-03-14 2012-05-02 Merck Sharp & Dohme Corp. Monocyclic anilide spirohydantoin cgrp receptor antagonists
JP4673294B2 (ja) 2003-03-14 2011-04-20 メルク・シャープ・エンド・ドーム・コーポレイション 二環式アニリドスピロヒダントインｃｇｒｐ受容体拮抗物質
WO2004091514A2 (en) 2003-04-15 2004-10-28 Merck & Co., Inc. Cgrp receptor antagonists
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
EP1646611A1 (en) 2003-07-15 2006-04-19 Merck & Co., Inc. Hydroxypyridine cgrp receptor antagonists
WO2005041757A2 (en) 2003-10-29 2005-05-12 University Of Rochester Detection of neuropeptides associated with pelvic pain disorders and uses thereof
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en) 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004018794A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2005102322A1 (de) 2004-04-20 2005-11-03 Boehringer Ingelheim International Gmbh Verwendung eines cgrp-antagonisten in kombination mit einem serotonin-wiederaufnahme-hemmer zur behandlung von migräne
DE102004027912A1 (de) 2004-06-09 2005-12-29 Grünenthal GmbH Substituierte Cyclopenten-Verbindungen
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
TWI432196B (zh) 2005-01-18 2014-04-01 Euro Celtique Sa 內臟痛的治療
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20100144767A1 (en) 2005-08-25 2010-06-10 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
JP5276982B2 (ja) 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
CA2623648C (en) 2005-09-21 2018-05-22 The Regents Of The University Of California Systems, compositions, and methods for local imaging and treatment of pain
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
SI3045182T1 (en) * 2005-11-14 2018-08-31 Teva Pharmaceuticals International Gmbh An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
CA2629406A1 (en) 2005-11-18 2007-05-31 Merck & Co., Inc. Spirohydantoin aryl cgrp receptor antagonists
WO2007076336A1 (en) * 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
JP5511379B2 (ja) 2006-07-21 2014-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｇｒｐレセプターアンタゴニスト
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
BRPI0819212A2 (pt) 2007-10-23 2015-06-16 Allergan Inc Métodos de tratamento de inflamação neurogênica crônica usando toxinas modificadas de clostrídio
KR101304150B1 (ko) 2008-03-04 2013-09-05 라브리스 바이올로직스 인코포레이티드 만성 통증의 치료 방법
MX2010009724A (es) 2008-03-04 2010-09-28 Pfizer Ltd Procedimientos de tratamiento del dolor inflamatorio-.
WO2009132309A1 (en) 2008-04-25 2009-10-29 Nellix, Inc. Stent graft delivery system
WO2010006168A2 (en) 2008-07-09 2010-01-14 University Of Rochester Methods of treating cancer using and agent that modulates activity of the calcitonin-gene related peptide ("cgrp") receptor
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
BR112012004464B8 (pt) 2009-08-28 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica
JO3330B1 (ar) 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
US8669368B2 (en) 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
PT3495392T (pt) 2011-05-20 2021-09-22 H Lundbeck As Composições anti-cgrp e a sua utilização
EA033109B1 (ru) 2011-05-20 2019-08-30 Олдербайо Холдингз Ллк Способы ингибирования, профилактики или лечения диареи и/или поддержания соответствующих уровней электролитов и жидкости в толстой кишке субъекта, подвергающегося связанному с диареей состоянию, с помощью антитела против cgrp или фрагмента антитела против cgrp
CN108014334B (zh) 2011-05-20 2021-11-30 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
CN110408644A (zh) * 2011-05-20 2019-11-05 奥尔德生物控股有限责任公司 多亚基蛋白质例如抗体在转化的微生物例如巴斯德毕赤酵母中的高纯度产生
SG2014011878A (en) 2011-08-19 2014-04-28 Alderbio Holdings Llc Multi-copy strategy for high-titer and high-purity production of multi-subunit proteins such as a antibodies in transformed microbes such as pichia pastoris
EP2802659A1 (en) 2012-01-10 2014-11-19 Noxxon Pharma AG Nucleic acids specifically binding cgrp
US8722060B2 (en) 2012-05-23 2014-05-13 William J. Binder Method of treating vertigo
EP2912643A1 (en) 2012-10-29 2015-09-02 Net Entertainment NE AB Architecture for multi-player, multi-game, multi- table, multi-operator&multi-jurisdiction live casino gaming
TWI636136B (zh) 2013-03-15 2018-09-21 艾爾德生物製藥股份有限公司 在酵母菌及其它轉型細胞中多肽高產量表現用之溫度變動技術
US20140287952A1 (en) 2013-03-15 2014-09-25 Alderbio Holdings Llc Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens
US20150017166A1 (en) 2013-07-03 2015-01-15 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
UY36302A (es) 2014-09-15 2016-04-29 Amgen Inc Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas
TWI728953B (zh) 2015-04-24 2021-06-01 美商安美基公司 治療或預防偏頭痛之方法
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
JP2018532728A (ja) 2015-09-24 2018-11-08 テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー （持続性）外傷後頭痛の予防、治療および低減
EP3515488A1 (en) 2016-09-23 2019-07-31 Teva Pharmaceuticals International GmbH Treating cluster headache
SMT202600087T1 (it) 2016-09-23 2026-03-09 Teva Pharmaceuticals Int Gmbh Trattamento dell’emicrania refrattaria
JP2021534197A (ja) 2018-08-22 2021-12-09 イーライ リリー アンド カンパニー 治療抵抗性患者のための抗ｃｇｒｐ抗体

Also Published As

Publication number Publication date
MX2016012188A (es) 2017-04-27
DK3119431T3 (da) 2024-03-18
PE20220337A1 (es) 2022-03-14
AU2015230933A1 (en) 2016-11-03
RS65360B1 (sr) 2024-04-30
JP2021121637A (ja) 2021-08-26
JP2019123750A (ja) 2019-07-25
PL3119431T3 (pl) 2024-06-24
ES2974803T3 (es) 2024-07-01
HUE065397T2 (hu) 2024-06-28
KR20200126018A (ko) 2020-11-05
PE20161439A1 (es) 2017-01-26
IL247853B (en) 2022-08-01
US9896502B2 (en) 2018-02-20
JP6892891B2 (ja) 2021-06-23
JP6568099B2 (ja) 2019-08-28
CN111973740A (zh) 2020-11-24
US20200331991A1 (en) 2020-10-22
EP4324481A3 (en) 2024-05-01
EA201691787A1 (ru) 2017-02-28
JP2021014464A (ja) 2021-02-12
US10519224B2 (en) 2019-12-31
SMT202400131T1 (it) 2024-05-14
ZA201606745B (en) 2022-12-21
NZ761478A (en) 2024-01-26
US11555064B2 (en) 2023-01-17
WO2015143409A1 (en) 2015-09-24
EP3119431A1 (en) 2017-01-25
KR20240146107A (ko) 2024-10-07
LT3119431T (lt) 2024-03-12
EP3119431A4 (en) 2017-09-06
CA2943551A1 (en) 2015-09-24
MX2020012816A (es) 2021-02-15
PT3119431T (pt) 2024-04-16
CL2016002375A1 (es) 2017-05-19
SI3119431T1 (sl) 2024-06-28
IL247853A0 (en) 2016-11-30
IL294490A (en) 2022-09-01
BR112016021423A2 (pt) 2017-11-14
MX378344B (es) 2025-03-10
US20150266948A1 (en) 2015-09-24
FI3119431T3 (fi) 2024-03-20
US20190031745A1 (en) 2019-01-31
UA123759C2 (uk) 2021-06-02
KR102274964B1 (ko) 2021-07-09
JP2024040245A (ja) 2024-03-25
JP2017510579A (ja) 2017-04-13
KR20160147755A (ko) 2016-12-23
CN106456759A (zh) 2017-02-22
CN113244387A (zh) 2021-08-13
EP4324481A2 (en) 2024-02-21
NZ724442A (en) 2021-02-26
HK1232129A1 (en) 2018-01-05
AU2015230933B2 (en) 2020-08-13
EP3119431B1 (en) 2024-01-24
HRP20240159T1 (hr) 2024-04-12

Similar Documents

Publication Publication Date Title
KR102274964B1 (ko) 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
US20260132189A1 (en) Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same
AU2006313434B2 (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EP3353202B1 (en) Preventing, treating, and reducing (persistent) post-traumatic headache
HK40041381A (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
NZ724442B2 (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HK1237668A1 (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EA043536B1 (ru) Антагонистические антитела, направленные против пептида, кодируемого геном кальцитонина, и способы их применения
EA052129B1 (ru) Антагонистические антитела, направленные против пептида, кодируемого геном кальцитонина, и способы их применения
HK40051844A (en) Antagonist antibodies directed against calcitonin gene-related peptide
HK1227724A1 (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HK1227724A (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HK1233955A1 (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
BR122020017648B1 (pt) Composição para o tratamento ou redução da incidência de enxaqueca compreendendo um anticorpo monoclonal que inibe a via do peptídeo relacionado ao gene da calcitonina

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104